<DOC>
	<DOCNO>NCT01353053</DOCNO>
	<brief_summary>The aim study ass whether graft patient survival , rejection rate renal graft function first year differ study arm . The investigator also evaluate reduction incidence cytomegalovirus improvement renal function everolimus 1 year .</brief_summary>
	<brief_title>Comparison Two Immunosuppressive Regimens Kidney Transplant Recipients With Deceased Donors With Aim Preventing Development Fibrosis / Atrophy Reducing Incidence Cytomegalovirus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Patients BMI 30 , first transplant PRA &lt; 30 , contraindication induction Thymoglobuline , age 18 year younger 70 year . patient BMI 30 retransplantation patient hypersensitized PRA &gt; 30 compare Thymoglobulina indication induction age 18 70 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>Cytomegalovirus</keyword>
	<keyword>Renal Transplant</keyword>
	<keyword>Atrophy/interstitial</keyword>
	<keyword>Conversion tacrolimus everolimus</keyword>
</DOC>